Dr. Joey Mattingly is the Founder and Principal for Drugscope andhas been in pharmacy for over twenty years, with pharmacy operations experience as an entry-level technician, staff pharmacist, pharmacy manager, district manager for a major pharmacy chain, and private equity start-up director for a long-term care pharmacy operation serving multiple states. Dr. Mattingly left the private sector in 2014 to pursue an academic career as an Assistant Professor at the University of Maryland School of Pharmacy while simultaneously earning his Doctor of Philosophy in Health Services Research with a specific focus on pharmacoeconomics.

Since 2014, Dr. Mattingly has developed a research portfolio that primarily focuses on drug pricing policy where he has engaged policymakers at local, state, and federal levels, including serving as Speaker of the House of Delegates and Trustee for the American Pharmacists Association (APhA) from 2019-2021. From November 2022 to April 2023, Dr. Mattingly served as an advisor to the Center of Medicare and Medicaid Services (CMS) to aid in the implementation of the new "Drug Price Negotiation Program" authorized by Congress through the Inflation Reduction Act. Most recently, he was named Research Fellow for the National Association of Insurance Commissioners (NAIC) to help inform policy on pharmacy benefit manager practices.

In addition to drug pricing, Dr. Mattingly has led or co-led multiple federal research proposals aimed at improving patient outcomes through a health equities research lens (U01FD007563 and U01MD017437). Additionally, he led a subaward to a large cooperative agreement with the Food and Drug Administration (U01FD005946) focused on improving diversity in patient engagement activities. This experience with health disparities research was intended to better understand policy implications that may exacerbate disparities in multiple priority populations to ensure our cost-effectiveness methods. incorporate health equity impacts.

Dr. Mattingly has previously served as an advisor of Effectiveness and Decision Science for the Patient-Centered Outcomes Research Institute, the Maryland Department of Health Prescription Drug Monitoring Program, and the Maryland Prescription Drug Affordability Stakeholder Council, He also serves as and Editorial Advisory Board member for the American Journal of Pharmaceutical Education and PharmacoEconomics- Open.